Related Experiment Videos
Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis
E M Schwarz1, R J Looney, R J O'Keefe
1Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA. Edward.Schwarz@URMC.Rochester.edu
Abstract:
Aseptic loosening of total joint arthroplastics due to periprosthetic osteolysis is a frequent cause of implant failure. The absence of clinical interventions to arrest or prevent this complication limits the use of total joint replacement especially in younger patients. Here we review recent studies implicating tumor necrosis factor (TNF)-alpha in periprosthetic osteolysis and the rationale for clinical studies of anti-TNF therapy and other interventions for periprosthetic loosening.
Insights
Periprosthetic osteolysis, a common cause of joint replacement failure, may be targeted by anti-tumor necrosis factor (TNF)-alpha therapies. Further research is needed to develop interventions for aseptic loosening and improve total joint replacement outcomes.
Area of Science:
- Orthopedic Surgery
- Immunology
- Biomaterials Science
Background:
- Aseptic loosening of total joint arthroplasties, driven by periprosthetic osteolysis, is a primary reason for implant failure.
- Current clinical interventions to prevent or halt this complication are limited, restricting joint replacement use in younger individuals.
- Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of periprosthetic osteolysis.
Purpose of the Study:
- To review recent studies investigating the role of TNF-alpha in periprosthetic osteolysis.
- To explore the rationale for clinical trials evaluating anti-TNF therapy for periprosthetic loosening.
- To discuss potential interventions for improving the longevity of total joint replacements.
Main Methods:
- Literature review of recent studies on periprosthetic osteolysis and TNF-alpha.
- Analysis of the role of inflammatory mediators in aseptic loosening.
- Examination of preclinical and clinical data supporting anti-TNF therapies.
Main Results:
- Evidence suggests TNF-alpha plays a significant role in the bone resorption associated with periprosthetic osteolysis.
- Preclinical models demonstrate that inhibiting TNF-alpha can reduce osteolysis.
- Clinical studies exploring anti-TNF agents are warranted to assess efficacy in preventing aseptic loosening.
Conclusions:
- Targeting TNF-alpha presents a promising therapeutic strategy for managing periprosthetic osteolysis.
- Developing effective interventions for aseptic loosening could enhance the success of total joint replacement, particularly in younger, more active patients.
- Further clinical investigation is crucial to validate the use of anti-TNF therapies and other interventions for periprosthetic loosening.